| Biomarker ID | 232 |
| PMID | 17460773 |
| Year | 2007 |
| Biomarker | C20ORF74 + DAPK1 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-DCC role in regulating apoptosis,Netrin-mediated signaling events,Bladder cancer,Apoptosis regulation,Interferon-gamma signaling pathway |
| Experiment | Benign Prostate Vs Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | Total of 56 patients were selected from Stanford Data set and were used for training. Rest of the samples from Stanford Data set, University of Michigan, University of Pittsburg were treated as validation sets. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.91 (Stanford); 0.64 (UM); 0.87 (Pittsburg) |
| Accuracy | NA |
| Level Of Significance | p<0.0005 |
| Method Used | NA |
| Clinical | No |
| Remarks | Results on Stanford Data Set (Validation Set). Classifier Used: IF (C20ORF74 + DAPK1) >= -0.7765 THEN PCA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | RALGAPA2, DAPK1 |